Hologic Inc. (HOLX) Given “Outperform” Rating at Leerink Swann
Several other analysts have also issued reports on HOLX. Piper Jaffray Cos. set a $44.00 price target on Hologic and gave the company a hold rating in a report on Sunday, August 28th. BTIG Research reissued a buy rating and set a $44.00 price target on shares of Hologic in a report on Thursday, July 28th. RBC Capital Markets reissued a sector perform rating and set a $39.00 price target (up previously from $37.00) on shares of Hologic in a report on Monday, August 1st. Zacks Investment Research lowered Hologic from a buy rating to a hold rating in a report on Friday, August 5th. Finally, Royal Bank Of Canada upped their price objective on Hologic from $37.00 to $39.00 and gave the stock a sector perform rating in a research note on Monday, August 1st. Six equities research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the stock. The stock has a consensus rating of Buy and an average target price of $42.71.
Shares of Hologic (NASDAQ:HOLX) traded up 1.59% during trading on Monday, hitting $39.50. The company had a trading volume of 348,025 shares. The stock has a market capitalization of $10.96 billion, a P/E ratio of 43.55 and a beta of 1.00. The firm’s 50 day moving average is $38.33 and its 200-day moving average is $36.10. Hologic has a 52 week low of $31.84 and a 52 week high of $41.66.
Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Wednesday, July 27th. The company reported $0.51 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.48 by $0.03. Hologic had a return on equity of 26.25% and a net margin of 9.39%. The business earned $717.40 million during the quarter, compared to analyst estimates of $703.66 million. During the same quarter in the previous year, the company posted $0.43 earnings per share. Hologic’s revenue for the quarter was up 3.4% on a year-over-year basis. Equities research analysts anticipate that Hologic will post $1.94 EPS for the current fiscal year.
In other news, Director Nancy Leaming sold 8,179 shares of the firm’s stock in a transaction on Thursday, July 21st. The stock was sold at an average price of $37.00, for a total value of $302,623.00. Following the completion of the sale, the director now owns 67,140 shares of the company’s stock, valued at approximately $2,484,180. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.84% of the stock is owned by insiders.
Hedge funds have recently bought and sold shares of the company. Thompson Siegel & Walmsley LLC raised its position in shares of Hologic by 1.2% in the second quarter. Thompson Siegel & Walmsley LLC now owns 4,176 shares of the company’s stock worth $144,000 after buying an additional 51 shares during the period. Norinchukin Bank The raised its position in shares of Hologic by 0.4% in the second quarter. Norinchukin Bank The now owns 12,724 shares of the company’s stock worth $440,000 after buying an additional 53 shares during the period. US Bancorp DE raised its position in shares of Hologic by 0.7% in the second quarter. US Bancorp DE now owns 13,542 shares of the company’s stock worth $468,000 after buying an additional 92 shares during the period. Calvert Investment Management Inc. raised its position in shares of Hologic by 0.8% in the second quarter. Calvert Investment Management Inc. now owns 15,244 shares of the company’s stock worth $527,000 after buying an additional 122 shares during the period. Finally, Raymond James Trust N.A. raised its position in shares of Hologic by 1.1% in the second quarter. Raymond James Trust N.A. now owns 21,989 shares of the company’s stock worth $761,000 after buying an additional 231 shares during the period. 94.51% of the stock is owned by hedge funds and other institutional investors.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.